Vita Coco Company, Inc.
Business
Vita Coco Company, Inc. is a beverage company that produces and markets coconut- and plant-based waters and related consumer products. It offers branded products including Vita Coco coconut water, coconut oil, coconut juice and milk offerings, Vita Coco Treats, Ever & Ever bottled water, and the PWR LIFT protein-infused drink, and also supplies private label and bulk products to retailers and food/beverage companies. The company operates through Americas and International business segments and sells both branded and private label lines using a contract manufacturing and co-packing model. Its products are sold in over 35 countries, with primary markets in North America, the U.K. and Germany, and distributed via club, grocery, mass, convenience, e-commerce, foodservice and various on-premise channels.
Summary from filing dated 2025-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net sales | 610 | 516 | 494 | 428 | 380 | |
| Cost of goods sold | 387 | 317 | 313 | 324 | 266 | |
| Gross profit | 223 | 199 | 181 | 103 | 113 | |
| Selling, general and administrative | 140 | 125 | 124 | 100 | 89 | |
| Total operating expenses | 140 | 125 | 124 | 100 | 89 | |
| Income from operations | 83 | 74 | 56 | 3 | 25 | |
| Unrealized gain/(loss) on derivative instruments | 5 | −8 | −872,000 | 7 | 2 | |
| Foreign currency loss | −1 | −2 | −251,000 | 1 | −2 | |
| Interest income, net | 7 | 7 | 3 | 51,000 | 127,000 | |
| Other income | 191,000 | 0 | 0 | — | — | |
| Total other income (expense) | 10 | −3 | 1 | 8 | −360,000 | |
| Income before income taxes | 93 | 71 | 58 | 11 | 24 | |
| Income tax expense | 22 | 15 | 11 | 3 | −5 | |
| Net income | 71 | 56 | 47 | 8 | 19 | |
| Foreign currency translation adjustment | 1 | −211,000 | 345,000 | — | — | |
| Total comprehensive income attributable to The Vita Coco Company, Inc. | — | — | 47 | — | — | |
| Basic (in dollars per share) | 1.25 | 0.99 | 0.83 | 0.14 | 0.35 | |
| Diluted (in dollars per share) | 1.19 | 0.94 | 0.79 | 0.14 | 0.35 | |
| Basic (in shares) | 57 | 57 | 56 | 56 | 54 | |
| Diluted (in shares) | 60 | 59 | 59 | 56 | 54 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 197 | 165 | 133 | 20 | 29 | |
| Accounts receivable, net of allowance of $2,660 at December 31, 2025, and $2,255 at December 31, 2024 | 82 | 63 | 50 | 43 | 47 | |
| Inventory | 111 | 84 | 51 | 84 | 75 | |
| Supplier advances, current | 693,000 | 954,000 | 2 | 2 | 1 | |
| Derivative assets | 732,000 | 1 | 4 | 4 | 126,000 | |
| Prepaid expenses and other current assets | 30 | 27 | 24 | 22 | 21 | |
| Total current assets | 421 | 341 | 263 | 175 | 173 | |
| Property and equipment, net | 9 | 2 | 2 | 2 | 2 | |
| Goodwill | 8 | 8 | 8 | 8 | 8 | |
| Supplier advances, long-term | 2 | 2 | 3 | 4 | 3 | |
| Deferred tax assets, net | 6 | 6 | 7 | 4 | 1 | |
| Right-of-use assets, net | 12 | 385,000 | 1 | 3 | 2 | |
| Other assets | 3 | 2 | 2 | 2 | 2 | |
| Total assets | 461 | 362 | 286 | 198 | 197 | |
| Accounts payable | 25 | 31 | 22 | 16 | 28 | |
| Accrued expenses and other current liabilities | 89 | 66 | 60 | 38 | 42 | |
| Notes payable, current | 3,000 | 10,000 | 13,000 | 23,000 | 28,000 | |
| Derivative liabilities | 2 | 7 | 1 | 71,000 | 3 | |
| Total current liabilities | 116 | 103 | 83 | 54 | 74 | |
| Notes payable, long-term | 0 | 3,000 | 13,000 | 25,000 | 48,000 | |
| Non-current portion of operating lease liabilities | 13 | 0 | — | — | — | |
| Other long-term liabilities | 97,000 | 295,000 | 647,000 | 2 | 301,000 | |
| Total liabilities | 130 | 104 | 83 | 57 | 74 | |
| Contingencies (See Note 11) | — | — | — | — | — | |
| Common stock, $0.01 par value; 500,000,000 shares authorized; 64,186,549 and 63,702,387 shares issued at December 31, 2025 and December 31, 2024, respectively; 57,082,173 and 56,961,941 shares outstanding at December 31, 2025 and December 31, 2024, respectively. | 642,000 | 637,000 | 631,000 | 622,000 | 618,000 | |
| Additional paid-in capital | 185 | 174 | 161 | 145 | 135 | |
| Retained earnings | 228 | 157 | 101 | 55 | 47 | |
| Accumulated other comprehensive gain (loss) | 486,000 | −860,000 | −649,000 | −994,000 | −616,000 | |
| Treasury stock, 7,104,376 shares at cost as of December 31, 2025, and 6,740,446 as of December 31, 2024. | −83 | −72 | −60 | −59 | −59 | |
| Total stockholders equity | 332 | 259 | 202 | 141 | 123 | |
| Total liabilities and stockholders equity | 461 | 362 | 286 | 198 | 197 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 1 | 745,000 | 660,000 | 2 | 2 | |
| Amortization of debt issuance costs | 16,000 | 0 | 0 | — | — | |
| Loss on disposal of equipment | 1,000 | 13,000 | 19,000 | 1,000 | 112,000 | |
| Provision for credit losses | 2 | 2 | 260,000 | 3 | 76,000 | |
| Stock-based compensation | 11 | 9 | 9 | 7 | 3 | |
| Impairment loss on assets held for sale | 0 | 0 | 363,000 | 619,000 | — | |
| Impairment loss on Runa assets | 185,000 | 0 | 0 | 7 | 0 | |
| Noncash lease expense | 1 | 1 | 1 | 1 | 0 | |
| Deferred tax expense | −366,000 | 644,000 | −2 | −3 | −2 | |
| Accounts receivable | −19 | −14 | −7 | 321,000 | −17 | |
| Inventory | −27 | −33 | 34 | −9 | −44 | |
| Prepaid expenses, net supplier advances, and other assets | 130,000 | −3 | −622,000 | −4 | 3 | |
| Accounts payable, accrued expenses, and other liabilities | 11 | 16 | 24 | −17 | 21 | |
| Net cash provided by operating activities | 47 | 43 | 107 | −11 | −16 | |
| Cash paid for property and equipment | −8 | −974,000 | −599,000 | −982,000 | −557,000 | |
| Proceeds from sale of property and equipment | 0 | 0 | 5,000 | 0 | 0 | |
| Equity method investment in joint venture | −104,000 | 0 | 0 | — | — | |
| Net cash used in investing activities | −8 | −974,000 | −594,000 | −982,000 | −557,000 | |
| Proceeds from exercise of stock awards | 4 | 4 | 7 | 3 | 177,000 | |
| Cash paid on notes payable | −10,000 | −13,000 | −23,000 | −28,000 | 21,000 | |
| Cash paid to acquire treasury stock | −11 | −12 | −773,000 | 0 | −50 | |
| Net cash provided by (used in) financing activities | −8 | −8 | 6 | 3 | −27 | |
| Effects of exchange rate changes on cash and cash equivalents | 834,000 | −563,000 | 387,000 | −178,000 | 35,000 | |
| Net increase in cash and cash equivalents | 32 | 33 | 113 | −9 | −43 | |
| Cash paid for interest | 0 | 1,000 | 75,000 | 217,000 | 349,000 |